EUVIMEDEUVIMED entdecken
Crossref

Clinicopathological Analysis of Immunologically High-Risk Kidney Transplantation Using High-Dose Intravenous Immunoglobulin as Desensitization Therapy

Tatsu Tanabe, Hajime Sasaki, Yutaka Shiono, Toyoshi Seito, Kazuhiro Ujihashi, Yusuke Takada, Haruka Higuchi, Daiji Takamoto, Keita Minami, Hiroshi Tanaka, Hiroshi Harada, Takahiro Tsuji und 1 weitere

Nephron · 2025

DOI: 10.1159/000548263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephron, 2025. Verfasst von Tatsu Tanabe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan, tanabetatsu@live.jp. Hauptthemen laut MEDLINE: Kidney Transplantation, Immunoglobulins, Intravenous, Desensitization, Immunologic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

High-dose intravenous immunoglobulin (H-IVIg) has been used as a desensitization therapy for donor-specific anti-HLA antibody (DSA)-positive kidney transplant recipients in Japan since 2019. This study reports the clinical and pathological outcomes of patients who received H-IVIg at Sapporo City General Hospital.

Methods

This study included 7 patients who underwent kidney transplantation at our hospital and received H-IVIg as pretransplant desensitization therapy. At our institution, H-IVIg is indicated for patients with a history of sensitization, such as prior blood transfusion, pregnancy, or organ transplantation, and who tested positive in a flow cytometry crossmatch (FCXM) before transplantation. The recipients (mean age: 55.2 ± 11 years) included one male and six females. The donors (mean age: 62.8 ± 8.8 years) included five males and two females. All were living donor transplants, with four cases involving spousal donation. We assessed the immunological status before and after desensitization and retrospectively analyzed kidney function, anti-donor antibody status, and pathological findings.

Results

Before desensitization, 6 patients were FCXM-T positive, and all were FCXM-B positive. After desensitization, 3 patients converted to FCXM-T negative; however, all remained FCXM-B positive. The Luminex single antigen test was positive in 4 patients before desensitization; one converted to negative, while one initially negative patient became positive. Consequently, 4 patients remained DSA positive at transplantation. Three patients experienced acute rejection within 1 month: one had antibody-mediated rejection (ABMR), and two had T-cell-mediated rejection. All patients responded to antirejection therapy, preserving their graft function. At 36 months of follow-up, all the patients survived with functional grafts. Pathological findings revealed early rejection in 3 patients, who later developed chronic ABMR. The remaining 4 patients did not experience rejection episodes.

Conclusion

The H-IVIg regimen facilitates kidney transplantation in immunologically high-risk recipients. However, the risk of early postoperative rejection and the potential development of chronic ABMR necessitate careful posttransplant monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationImmunoglobulins, IntravenousDesensitization, ImmunologicHumansMaleFemaleMiddle AgedGraft RejectionRetrospective StudiesAgedHLA AntigensAdultIsoantibodies

Stichwörter der Autor:innen

Desensitization protocolFlow cytometry crossmatch positiveHigh-dose intravenous immunoglobulinKidney transplant

Substanzen

Immunoglobulins, IntravenousHLA AntigensIsoantibodies

Autor:innen und Institutionen

  • Department of Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan, tanabetatsu@live.jp.
  • Department of Kidney Transplant Surgery and Urology, Sapporo City General Hospital, Sapporo, Japan.
  • Department of Pathology, Sapporo City General Hospital, Sapporo, Japan.
  • Department of Urology, Hokkaido University Hospital, Sapporo, Japan.

Zitieren

APA

Tanabe, T., Sasaki, H., Shiono, Y., Seito, T., Ujihashi, K., Takada, Y., Higuchi, H., Takamoto, D., Minami, K., Tanaka, H., Harada, H., Tsuji, T., & Hotta, K. (2025). Clinicopathological Analysis of Immunologically High-Risk Kidney Transplantation Using High-Dose Intravenous Immunoglobulin as Desensitization Therapy. Nephron. https://doi.org/10.1159/000548263

Vancouver

Tanabe T, Sasaki H, Shiono Y, Seito T, Ujihashi K, Takada Y, et al. Clinicopathological Analysis of Immunologically High-Risk Kidney Transplantation Using High-Dose Intravenous Immunoglobulin as Desensitization Therapy. Nephron. 2025. doi:10.1159/000548263

BibTeX
@article{Tanabe2025,
  author = {Tanabe, Tatsu and Sasaki, Hajime and Shiono, Yutaka and Seito, Toyoshi and Ujihashi, Kazuhiro and Takada, Yusuke and Higuchi, Haruka and Takamoto, Daiji and Minami, Keita and Tanaka, Hiroshi and Harada, Hiroshi and Tsuji, Takahiro and Hotta, Kiyohiko},
  title = {Clinicopathological Analysis of Immunologically High-Risk Kidney Transplantation Using High-Dose Intravenous Immunoglobulin as Desensitization Therapy},
  journal = {Nephron},
  year = {2025},
  doi = {10.1159/000548263}
}
Kostenlos starten →